Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4465MR)

This product GTTS-WQ4465MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4465MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1477MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ5056MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ11461MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ15006MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ2099MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ7678MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ8641MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ3809MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW